| Literature DB >> 19643208 |
Emese Kiss1, Laszlo Kovacs, Peter Szodoray.
Abstract
Systemic lupus erythematosus (SLE) is a prototypical systemic autoimmune disease, characterized by a wide array of symptoms and organ involvements, leading to varying disease courses and outcome, and ranging from mild to severe types. In patients with SLE, the incidence and risk of malignancy development is increased, and mostly non-Hodgkin's lymphoma (NHL), cervical cancer, as well as bronchial carcinomas occur. Besides others, the common genetic predisposition, chronic antigen stimulus, disproportional immune responses, as well as the chronic administration of immunosuppressive medications can contribute to the development of malignancies in lupus. In this review we present the molecular pathology, as well as the epidemiological and clinical aspects of malignancies in patients with SLE. Copyright 2009 Elsevier B.V. All rights reserved.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19643208 PMCID： PMC3880771 DOI： 10.1016/j.autrev.2009.07.004
Source DB: PubMed Journal: Autoimmun Rev ISSN： 1568-9972 Impact factor: 9.754